amgen
FDA Halts Amgen’s Phase 1 Obesity Drug Trial: AMG 513 Study on Hold
Amgen, obesity drug, AMG 513, FDA clinical hold, Phase 1 trial, pharmaceutical setback
Amgen and Celltrion Reach Settlement in Denosumab Patent Litigation, Paving Way for Mid-2025 Biosimilar Launch
Amgen, Celltrion, denosumab, patent litigation, biosimilar, settlement, launch date
Amgen Expands in North Carolina with $1 Billion Biomanufacturing Facility
Amgen, North Carolina, biomanufacturing, facility expansion, pharmaceutical industry
Amgen’s MariTide Shows Promising 20% Weight Loss, Falls Short of Investor Expectations
Amgen, MariTide, weight loss, obesity treatment, clinical trial results
Amgen Appoints Howard Chang as Senior Vice President of Research and Chief Scientific Officer
Howard Chang, Amgen, Chief Scientific Officer, Research, Biotechnology, Pharmaceutical Industry
AstraZeneca and Amgen’s Tezspire Shows Efficacy in Phase 3 Trial for Chronic Rhinosinusitis with Nasal Polyps, Despite Regulatory Risk Concerns
Tezspire, AstraZeneca, Amgen, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Phase 3 Trial, Regulatory Risk
Tezspire Shows Promise in Treating Chronic Rhinosinusitis with Nasal Polyps
Tezspire, chronic rhinosinusitis with nasal polyps (CRSwNP), AstraZeneca, Amgen, WAYPOINT trial, TSLP inhibitor, nasal congestion, nasal polyps.
Amgen Refocuses Pipeline, Prioritizes Obesity Therapies Amid Strategic Cuts
Amgen, Obesity Therapies, Pipeline Cuts, Strategic Refocus, MariTide, Phase 3 Program
FDA Delays Decision on Full Approval for Amgen’s Lumakras and Intercept’s Ocaliva
FDA, PDUFA, Amgen, Intercept, Lumakras, Ocaliva, metastatic colorectal cancer, primary biliary cholangitis
FDA Delays Decision on Amgen’s Lumakras and Vectibix Combination for Metastatic Colorectal Cancer
FDA, Amgen, Lumakras, Vectibix, metastatic colorectal cancer, KRAS G12C mutation, sotorasib, panitumumab